Articles related to PSYCHOPHARMACOLOGY

In a phase 3 trial of 214 adults with generalized anxiety disorder, a single dose of DT120 orally disintegrating tablets produced greater reductions in anxiety scores than placebo through 12 weeks. Full peer-reviewed data and longer-term results remain pending.

A post hoc analysis of five brexpiprazole trials found improved functioning in adults with schizophrenia, including those with baseline hostility or agitation. The exploratory findings require interpretation alongside trial-design limitations and lack of multiplicity adjustment.

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.

A meta-analysis of seven studies found cannabinoid-based therapies were associated with lower agitation and neuropsychiatric symptom scores in patients with moderate to severe Alzheimer disease. Cognitive benefits were not consistently observed, and somnolence occurred more frequently with treatment.

Creatine supplementation showed mixed effects on depressive symptoms across five randomized trials involving patients with mood disorders. The early findings suggest potential adjunctive benefit in some populations but do not establish a consistent treatment effect.

Viral claims described the ketogenic diet as a cure for schizophrenia despite limited supporting evidence. Available research consists of small pilot studies, while established treatment approaches continue to rely on pharmacologic and psychosocial interventions.